Global Dry Eye Syndrome Drugs Market 2017-2021
About Dry Eye Syndrome Drugs
Dry eye syndrome, also known as keratoconjunctivitis sicca, is the condition of having dry eyes where either the eyes are not capable of producing sufficient tears to maintain lubrication or the when produced, they evaporate too quickly. The condition can lead to various difficulties in the daily life of a person, such as reading for an extended period of time or using a computer. The condition can decrease the tolerance of a person in a dry environment such as air present inside an airplane.
Technavio’s analysts forecast the global dry eye syndrome drugs market to grow at a CAGR of 7.59% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global dry eye syndrome drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Dry Eye Syndrome Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global dry eye syndrome drugs market: Allergan, Novartis, Otsuka Holdings, and Santen Pharmaceutical.
Other Prominent Vendors in the market are: Aerie Pharmaceutical, Akorn, Bausch & Lomb, Johnson & Johnson, Merck, MIMETOGEN, ReGenTree, Sun Pharmaceutical, and Teva Pharmaceutical.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is Initiatives and programs for supporting patients with ophthalmic disorders. Public awareness about problems related to visual impairment has increased in the last decade because of the increase in the number of government initiatives undertaken by various organizations.”
According to the report, one driver in the market is untapped potential in developing countries. Countries such as India, China, and Brazil are some of the most attractive countries for pharmaceutical companies globally. Several factors are responsible for the high growth of the healthcare sector in developing countries. Vast population, growing geriatric population, and lifestyle disorders such as obesity and diabetes that lead to dry eye syndrome are factors expected to drive the market in developing countries.
Further, the report states that one challenge in the market is lack of ophthalmology experts. The lack of trained ophthalmologists who have expertise in treating eye disorders such as dry eyes is one of the key challenges in the market. Although the number of people diagnosed with or prone to eyesight disorders has been on the rise, there are insufficient trained and experienced eye care professionals (ophthalmologists, optometrists, ophthalmic assistants, and ophthalmic nurses) to treat eye disorders. For instance, in Europe, there is just one ophthalmologist for every 8,000 individuals.
Allergan, Novartis, Otsuka Holdings, Santen Pharmaceutical, Aerie Pharmaceutical, Akorn, Bausch & Lomb, Johnson & Johnson, Merck, MIMETOGEN, ReGenTree, Sun Pharmaceutical, and Teva Pharmaceutical.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook